STK11 mutation

News alerts, weekly reports and conference planners

Entrez ID:

6794

Related biomarkers:

‹

›

STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	nivolumab Resistant: B - Late Trials nivolumab Resistant : B	nivolumab Resistant: B - Late Trials nivolumab Resistant : B
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	DRP-104 Sensitive: B - Late Trials DRP-104 Sensitive : B	DRP-104 Sensitive: B - Late Trials DRP-104 Sensitive : B
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	durvalumab Resistant: B - Late Trials durvalumab Resistant : B	durvalumab Resistant: B - Late Trials durvalumab Resistant : B
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	Sensitive: B - Late Trials Sensitive : B	Sensitive: B - Late Trials Sensitive : B
STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer	STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	BGB324 Sensitive: B - Late Trials BGB324 Sensitive : B	BGB324 Sensitive: B - Late Trials BGB324 Sensitive : B
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	pembrolizumab + BGB324 Sensitive: B - Late Trials pembrolizumab + BGB324 Sensitive : B	pembrolizumab + BGB324 Sensitive: B - Late Trials pembrolizumab + BGB324 Sensitive : B
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	bevacizumab + atezolizumab Sensitive: B - Late Trials bevacizumab + atezolizumab Sensitive : B	bevacizumab + atezolizumab Sensitive: B - Late Trials bevacizumab + atezolizumab Sensitive : B
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B
STK11 mutation	Solid Tumor	STK11 mutation	Solid Tumor	TNG260 Sensitive: C2 – Inclusion Criteria TNG260 Sensitive : C2	TNG260 Sensitive: C2 – Inclusion Criteria TNG260 Sensitive : C2
STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer	STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer	docetaxel Resistant: C3 – Early Trials docetaxel Resistant : C3	docetaxel Resistant: C3 – Early Trials docetaxel Resistant : C3
STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer	STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Resistant: C3 – Early Trials atezolizumab Resistant : C3	atezolizumab Resistant: C3 – Early Trials atezolizumab Resistant : C3
STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer	STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	cetuximab + avelumab Resistant: C3 – Early Trials cetuximab + avelumab Resistant : C3	cetuximab + avelumab Resistant: C3 – Early Trials cetuximab + avelumab Resistant : C3
STK11 mutation	Lung Adenocarcinoma	STK11 mutation	Lung Adenocarcinoma	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer	STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer	durvalumab Resistant: C3 – Early Trials durvalumab Resistant : C3	durvalumab Resistant: C3 – Early Trials durvalumab Resistant : C3
STK11 mutation	Cervical Cancer	STK11 mutation	Cervical Cancer	anlotinib + sintilimab Resistant: C3 – Early Trials anlotinib + sintilimab Resistant : C3	anlotinib + sintilimab Resistant: C3 – Early Trials anlotinib + sintilimab Resistant : C3
STK11 mutation	Solid Tumor	STK11 mutation	Solid Tumor	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	pembrolizumab + ramucirumab Sensitive: C3 – Early Trials pembrolizumab + ramucirumab Sensitive : C3	pembrolizumab + ramucirumab Sensitive: C3 – Early Trials pembrolizumab + ramucirumab Sensitive : C3
STK11 mutation	Pituitary Gland Carcinoma	STK11 mutation	Pituitary Gland Carcinoma	temozolomide + capecitabine Resistant: C4 – Case Studies temozolomide + capecitabine Resistant : C4	temozolomide + capecitabine Resistant: C4 – Case Studies temozolomide + capecitabine Resistant : C4
STK11 mutation	Pituitary Gland Carcinoma	STK11 mutation	Pituitary Gland Carcinoma	everolimus Sensitive: C4 – Case Studies everolimus Sensitive : C4	everolimus Sensitive: C4 – Case Studies everolimus Sensitive : C4
STK11 mutation	Pancreatic Cancer	STK11 mutation	Pancreatic Cancer	everolimus Sensitive: C4 – Case Studies everolimus Sensitive : C4	everolimus Sensitive: C4 – Case Studies everolimus Sensitive : C4
STK11 mutation	Lung Non-Small Cell Squamous Cancer	STK11 mutation	Lung Non-Small Cell Squamous Cancer	pembrolizumab Resistant: C4 – Case Studies pembrolizumab Resistant : C4	pembrolizumab Resistant: C4 – Case Studies pembrolizumab Resistant : C4
STK11 mutation	Lung Adenocarcinoma	STK11 mutation	Lung Adenocarcinoma	abemaciclib Sensitive: C4 – Case Studies abemaciclib Sensitive : C4	abemaciclib Sensitive: C4 – Case Studies abemaciclib Sensitive : C4
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	APG-115 Sensitive: D – Preclinical APG-115 Sensitive : D	APG-115 Sensitive: D – Preclinical APG-115 Sensitive : D
STK11 mutation	Lung Cancer	STK11 mutation	Lung Cancer	dasatinib + selumetinib + RTB101 Sensitive: D – Preclinical dasatinib + selumetinib + RTB101 Sensitive : D	dasatinib + selumetinib + RTB101 Sensitive: D – Preclinical dasatinib + selumetinib + RTB101 Sensitive : D
STK11 mutation	Lung Cancer	STK11 mutation	Lung Cancer	dasatinib Resistant: D – Preclinical dasatinib Resistant : D	dasatinib Resistant: D – Preclinical dasatinib Resistant : D
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	sirolimus Sensitive: D – Preclinical sirolimus Sensitive : D	sirolimus Sensitive: D – Preclinical sirolimus Sensitive : D
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	CI-1040 Sensitive: D – Preclinical CI-1040 Sensitive : D	CI-1040 Sensitive: D – Preclinical CI-1040 Sensitive : D

STK11 mutation

Associations